CannaVcell Sciences Inc. (CSE:CNVC) (“CannaVcell”) announced last Thursday, the first production of Cannabis cells in suspension, with a cannabinoid profile identical to that of the original cannabis plant – without the need to grown the plant itself. The achievement was possible using the breakthrough and patented BioHarvest’s technology (CannaVcell is the worldwide exclusive licensee of the technology for cannabis application). (See NR: www.cannavcell.com).

cannavcell


Figure 1 presents identical THCA and CBDA profiles for cannabis cells grown in liquid suspension as those found in actual cannabis flowers.

To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/6168/48318_7e0eb946e4f9fb71_006full.jpg

cannavcell

Figure 2 shows Cannabis cells powder that was produced in a small scale bioreactor (true picture).

To view an enhanced version of Figure 2, please visit:
https://orders.newsfilecorp.com/files/6168/48318_7e0eb946e4f9fb71_005full.jpg

The Bioharvest technology, called biofarming, mirrors nature without any solvent extraction, genetic modification or synthetic molecular processing. In regard to Cannabis, biofarming end result is a cannabis powder with the identical composition of cannabinoids as those found in the cannabis plant. The original plant is used only once to collect its cannabis cells with the active ingredients that are subsequently perpetually reproduced with the same quality and consistency.

Dr. Yochi Hagay, CTO of BioHarvest. Dr. Hagay added, “We are the first company in the world that has been able to grow cannabis cells that produce six (6) different types of cannabinoids THCA, THC, CBDA, CBD, CBN, CBC, all of which are identical to the cannabinoids produced in the relevant Cannabis flower.”

cannavcell

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6168/48318_cv2.jpg

COPY/PASTE REGISTRATION LINK: https://attendee.gotowebinar.com/register/8500294009813134092

Dr. Zaki Rakib, Co-Founder & CEO: “This achievement marks a turning point in the Cannabis Community. The revolution is here, is now! I invite the public and the Cannabis Industry, to joint me for a live webinar this Wednesday October 2nd, 2019 at 8:00 AM Pacific Daylight Time.”

About Canna-V-Cell Sciences Inc.

Based in Vancouver BC, Canna-V-Cell Sciences Inc. (CNVC) is the exclusive Cannabis worldwide licensee of the proprietary and patent protected BioHarvest technology. It is the first and only industrial large-scale plant cell growth technology capable of directly and constantly producing the active plant ingredients without the necessity to grow the plant itself. By adopting this technology and building adequate cells production capacity, Canna-V-Cell’s objective is to become the lead- ing supplier of Cannabis for both the medicinal and recreational legal use.

Canna-V-Cell Sciences Inc.
Dr. Zaki Rakib
Co-Founder & CEO

For further info, please contact: Email: inquiries@cannavcellsciences.ca Local: 604.373.4774 Toll Free: 833.727.4774

Forward-Looking Statements Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management’s current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company’s control. Such factors include, among other things, risks and uncertainties relating to the fact that the Company would require additional funds in order to construct a commercial biochamber facility and risks related to the adaption of the BioHarvest technology to cannabis. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

Neither Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

cannavcell

To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6168/48318_cv4.jpg

Click here to connect with Canna-V-Cell Sciences Inc. (CSE:CNVC) for an Investor Presentation.

Source

 

Cannabis - Will The Fortune 500 Join The Party?

 
Our Exclusive FREE Report Contains Information You NEED To Know About Cannabis Stock Investing!
 
  • The Cannabis Derivatives are derived from Avicanna’s cultivation and extraction infrastructure in Santa Marta, Colombia designed to supply partner companies and the manufacture of Avicanna’s own finished products.

Avicanna Inc. (” Avicanna ” or the ” Company “) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, is pleased to announce that, through its majority owned Colombian subsidiary, Santa Marta Golden Hemp S.A.S. (“ SMGH ”), it has completed a commercial exports of CBD Isolate and CBD full spectrum psychoactive cannabis resin (the “ Cannabis Derivatives ”) to a leading Chilean homeopathic and naturopathic pharmaceutical company.

The Cannabis Derivatives, branded as Aureus™, are cultivated, extracted, and manufactured by SMGH. In addition, for Avicanna’s global input needs, SMGH also supplies other pharmaceutical and cosmetics companies with cannabinoids including CBD, THC, and rare cannabinoids such as CBG in addition to supplying global cultivation companies with standardized and feminized seeds. This new export to Chile is a recurring order and part of on-going relationship with an established homeopathic Chilean company.

Keep reading... Show less

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX:WEED, NASDAQ:CGC) will release its financial results for the second quarter fiscal year 2022 ended September 30, 2021 before financial markets open on November 5, 2021 .

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco Labs” or “the Company”), a vertically integrated multistate operator and the number one U.S. wholesaler of branded cannabis products, announced today the opening of a new Sunnyside dispensary in Wyomissing, Pennsylvania. Wyomissing will be Cresco Labs’ fifth dispensary in Pennsylvania and 38 th nationwide.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211021006075/en/

Keep reading... Show less

The world of cannabis consumption is set to change radically, thanks in large part to the advancement of state-of-the-art research on the plant itself.

Medical cannabis products have already allowed many new users to discover the plant’s potential, but decisive research will help build a foundation for more sophisticated medical offerings.

Keep reading... Show less

ADASTRA HOLDINGS LTD. ENGAGES HYBRID FINANCIAL LTD.

Adastra Holdings Ltd. (formerly Phyto Extractions Inc.) (CSE: XTRX) (FRA: D2EP) (“Adastra”, or the “Company”) is pleased to announce that it has retained Hybrid Financial Ltd. (“Hybrid”) to provide marketing services to the Company. Hybrid has been engaged to heighten market and brand awareness for Adastra and to broaden the Company’s reach within the investment community.

Keep reading... Show less